#956

6 trials

Sponsors

Sanofi Synthelabo India Limited, Sanofi Synthelabo A Sir Mathuradas Vasanji Road AndheriE Mumbai India, Sanofi Synthelabo A Sir Mathuradas Vasanji Road AndheriE Mumbai, Merck KGaA, Frankfurter Str. 25,0 64293 Darmstadt, Germany, Intercell USA, Inc. (Intercell) 20 Firstfield Road Gaithersburg, Maryland 20878 United States of America (USA)

Conditions

Health Condition 1: null- In Patients With Type 2 Diabetes insufficiently controlled with basal insulin for the assessment of the efficacy and Safety Evaluation Health Condition 2: E119- Type 2 diabetes mellitus without complicationsHealth Condition 1: null- Type 2 Diabetes for Glycemic Control and Safety Evaluation Health Condition 2: E116- Type 2 diabetes mellitus with other specified complicationsHealth Condition 1: null- Type 2 Diabetes for Glycemic Control and Safety Evaluation Health Condition 2: E119- Type 2 diabetes mellitus without complicationsHealth Condition 1: null- chemotherapy induced thrombocytopenia

Phase 2

ELT209: A Phase Two, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of the Travelers Diarrhea Vaccine System in Travelers to Asia.

Active, not recruitingCTRI/2009/091/000802

Intercell USA, Inc. (Intercell) 20 Firstfield Road Gaithersburg, Maryland 20878 United States of America (USA)

Target: 716Updated: 2021-11-24

Phase 3

A clinical trial to study the efficacy and safety of AVE0010 in patients with type 2 diabetes not treated with antidiabetic agents

Active, not recruitingCTRI/2008/091/000071

Sanofi Synthelabo India LimitedHealth Condition 1: null- Type 2 Diabetes for Glycemic Control and Safety Evaluation Health Condition 2: E116- Type 2 diabetes mellitus with other specified complications

Target: 361Updated: 2021-11-24

A clinical study to evaluate the effects of GLP-1 agonist AVE0010 in paTients with type 2 diabetes mellitus for Glycemic cOntrol and sAfety evaLuation, on top of Sulfonylurea

Active, not recruitingCTRI/2008/091/000176

Sanofi Synthelabo A Sir Mathuradas Vasanji Road AndheriE Mumbai IndiaHealth Condition 1: null- Type 2 Diabetes for Glycemic Control and Safety Evaluation Health Condition 2: E119- Type 2 diabetes mellitus without complications

Target: 855Updated: 2021-11-24

GLP-1 Agonist AVE0010 in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation, on Top of Basal Insulin

Active, not recruitingCTRI/2008/091/000180

Sanofi Synthelabo A Sir Mathuradas Vasanji Road AndheriE MumbaiHealth Condition 1: null- In Patients With Type 2 Diabetes insufficiently controlled with basal insulin for the assessment of the efficacy and Safety Evaluation Health Condition 2: E119- Type 2 diabetes mellitus without complications

Target: 496Updated: 2021-11-24

A clinical trial to study the effects of Oprelvekin in patients with in prevention and treatment of chemotherapy induced thrombocytopenia in adult cancer patients.

Active, not recruitingCTRI/2009/091/001086

Lupin LimitedHealth Condition 1: null- chemotherapy induced thrombocytopenia

Target: 60Updated: 2021-11-24

STRIDE - A Randomised, Double-Blind, Phase III Study of Stimuvax® in combination with Hormonal Treatment versus Hormonal Treatment alone for First-line Therapy of endocrine-sensitive Advanced Breast Cancer

Active, not recruitingCTRI/2009/091/000660

Merck KGaA, Frankfurter Str. 25,0 64293 Darmstadt, Germany

Target: 909Updated: 2021-11-24